These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37900721)

  • 21. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?
    Yang J; Cosman F; Stone PW; Li M; Nieves JW
    Osteoporos Int; 2020 Dec; 31(12):2321-2335. PubMed ID: 32778935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
    Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
    J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
    Mueller D; Gandjour A
    Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.
    Walter E; Dellago H; Grillari J; Dimai HP; Hackl M
    Bone; 2018 Mar; 108():44-54. PubMed ID: 29269173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management.
    Soini E; Riekkinen O; Kröger H; Mankinen P; Hallinen T; Karjalainen JP
    Clinicoecon Outcomes Res; 2018; 10():279-292. PubMed ID: 29881300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis.
    Mueller D; Weyler E; Gandjour A
    Pharmacoeconomics; 2008; 26(6):513-36. PubMed ID: 18489201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
    Schwenkglenks M; Lippuner K
    Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of Fracture Liaison Services Compared with Standard of Care in the Secondary Prevention of Fragility Fractures in Spain.
    Naranjo A; Prieto-Alhambra D; Sánchez-Martín J; Pérez-Mitru A; Brosa M
    Clinicoecon Outcomes Res; 2022; 14():249-264. PubMed ID: 35492806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
    Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
    Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
    Moriwaki K; Noto S
    Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS).
    Adams AL; Fischer H; Kopperdahl DL; Lee DC; Black DM; Bouxsein ML; Fatemi S; Khosla S; Orwoll ES; Siris ES; Keaveny TM
    J Bone Miner Res; 2018 Jul; 33(7):1291-1301. PubMed ID: 29665068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.
    Li N; Zheng B; Liu M; Zhou H; Zhao L; Cai H; Huang J
    Menopause; 2019 Aug; 26(8):906-914. PubMed ID: 30994577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.